Ustekinumab: moving the target from psoriasis to Crohn's disease.
about
Th17 cells in autoimmune and infectious diseasesRecent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targetsUstekinumab in Crohn's disease: evidence to date and place in therapyPro-inflammatory miR-223 mediates the cross-talk between the IL23 pathway and the intestinal barrier in inflammatory bowel disease.Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.The integrated disease network.
P2860
Ustekinumab: moving the target from psoriasis to Crohn's disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Ustekinumab: moving the target from psoriasis to Crohn's disease.
@en
type
label
Ustekinumab: moving the target from psoriasis to Crohn's disease.
@en
prefLabel
Ustekinumab: moving the target from psoriasis to Crohn's disease.
@en
P2093
P2860
P1476
Ustekinumab: moving the target from psoriasis to Crohn's disease.
@en
P2093
Alessia Settesoldi
Francesca Rogai
Manuela Coppola
Vito Annese
P2860
P356
10.1586/17474124.2014.850414
P577
2013-11-25T00:00:00Z